Hormonal
Tirzepatide, a GIP/GLP-1 receptor agonist administered via once-weekly subcutaneous injections, produces clinically significant reductions in HbA1c and body weight in patients with type 2 diabetes, demonstrating superior efficacy compared to standard antidiabetic therapies including GLP-1 RAs and insulin.
Tirzepatide is a once-weekly injection for type 2 diabetes that lowers blood sugar and reduces weight more effectively than many existing treatments. It starts at a low dose to minimize side effects like nausea, which usually improve over time. Patients should continue lifestyle changes like diet and exercise alongside the medication.
Tirzepatide dose-dependently leads to clinically significant reductions in glycemic parameters and body weight and has been shown to have stronger effects in reducing these parameters than standard antidiabetic therapy.
Why this rating
Supported by multiple phase III randomized controlled trials (SURPASS program) with large sample sizes.
Source
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Baptist Gallwitz · Frontiers in Endocrinology · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →